Effect of raloxifene on fractures in postmenopausal women with or at risk for coronary heart disease: The raloxifene use for the heart (RUTH) study

被引：0
|
作者：
Ensrud, Kristine E.
Stock, John L.
Grady, Deborah
Barrett-Connor, Elizabeth
Mosca, Lori
Khaw, Kay-Tee
Zhao, Qingwen
Agnusdei, Donato
Dalsky, Gail P.
Cauley, Jane A.
机构：
[1] VAMC, Minneapolis, MN USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] Columbia Univ, Med Ctr, New York, NY USA
[7] Univ Cambridge, Sch Clin Med, Cambridge, England
[8] Eli Lilly & Co, Burlington, CT USA
[9] Univ Pittsburgh, Pittsburgh, PA USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S234 / S235
页数：2
相关论文
共 50 条
  • [31] The effect of raloxifene on gonadotrophins, prolactin and lipids in postmenopausal women
    Izol Torun, A. N.
    Emral, R.
    Corapcioglu, D.
    Uysal, A. R.
    Kamel, N.
    Tonyukuk Gedik, V
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S238 - S238
  • [32] Effect of Raloxifene Treatment on Osteocyte Apoptosis in Postmenopausal Women
    Huib W. van Essen
    Paulien J. Holzmann
    Marinus A. Blankenstein
    Paul Lips
    Nathalie Bravenboer
    Calcified Tissue International, 2007, 81 : 183 - 190
  • [33] Effect of raloxifene therapy on venous thromboembolism in postmenopausal women
    Adomaityte, Jurga
    Farooq, Maria
    Qayyum, Rehan
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) : 338 - 342
  • [34] The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women
    Neven, P
    Goldstein, SR
    Ciaccia, AV
    Zhou, LF
    Silfen, SL
    Muram, D
    GYNECOLOGIC ONCOLOGY, 2002, 85 (02) : 388 - 390
  • [35] Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease
    Manuel Sosa
    Pedro Saavedra
    María Jesús Gómez de Tejada
    José Mosquera
    Ramón Pérez-Cano
    José Manuel Olmos
    Manuel Muñoz-Torres
    María José Amérigo
    María Jesús Moro
    Manuel Díaz-Curiel
    Javier Alegre
    Jorge Malouf
    Javier del Pino
    Xavier Nogués
    Antonio Torrijos
    Aging Clinical and Experimental Research, 2011, 23 (2) : 112 - 117
  • [36] Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease
    Manuel Sosa
    Pedro Saavedra
    María Jesús Gómez de Tejada
    José Mosquera
    Ramón Pérez-Cano
    José Manuel Olmos
    Manuel Muñoz-Torres
    María José Amérigo
    María Jesús Moro
    Manuel Díaz-Curiel
    Javier Alegre
    Jorge Malouf
    Javier del Pino
    Xavier Nogués
    Antonio Torrijos
    Aging Clinical and Experimental Research, 2011, 23 : 112 - 117
  • [37] Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease
    Sosa, Manuel
    Saavedra, Pedro
    Jesus Gomez de Tejada, Maria
    Mosquera, Jose
    Perez-Cano, Ramon
    Manuel Olmos, Jose
    Munoz-Torres, Manuel
    Jose Amerigo, Maria
    Jesus Moro, Maria
    Diaz-Curiel, Manuel
    Alegre, Javier
    Malouf, Jorge
    del Pino, Javier
    Nogues, Xavier
    Torrijos, Antonio
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 23 (02) : 112 - 117
  • [38] Raloxifene decreases the risk of new moderate or severe vertebral fractures in postmenopausal women with osteoporosis.
    Adachi, J
    Crans, GG
    Lu, Y
    Fuerst, T
    Wong, M
    Harper, KD
    Siris, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S255 - S255
  • [39] Study confirms that raloxifene reduces risk of invasive breast cancer in postmenopausal women
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (05): : 669 - 669
  • [40] Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial
    Kanis, JA
    Johnell, O
    Black, DM
    Downs, RW
    Sarkar, S
    Fuerst, T
    Secrest, RJ
    Pavo, I
    BONE, 2003, 33 (03) : 293 - 300
12345